HDAC8 and hepatocellular carcinoma: In a syngeneic and orthotopic C57BL/6 mouse Hepa1-6 hepatoma model, selective HDAC8 inhibitor PCI -34051 combined with anti-PD-L1 therapy improved tumor-infiltrating CD8+ T cells, eliciting an effective and up to 15-month tumor-free response to ICB.